AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04354428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy
Study NCT04354428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
Study NCT04354428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Eligible participants in a household will receive folic acid and an additional intervention drug
Study NCT04354428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Eligible participants in a household will receive folic acid and an additional intervention drug
Study NCT04354428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Description: Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
Study NCT01639430 — intervention group
Intervention type: OTHER
Intervention: rectal, tympanal and temporal artery thermometry
Description: Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well.
Study NCT03291314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].
Study NCT03291314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
Study NCT01564706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose
Study NCT03670459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey exercises
Description: Eye movements and head movements
Study NCT03670459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular habituation exercises
Description: Move from a sitting position to flat on the back
Study NCT03670459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercises
Description: Weight Shift Forward and Back
Study NCT01380054 — intervention group
Intervention type: BEHAVIORAL
Intervention: Evaluation of quality of life
Description: -Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
Study NCT03631576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123/CLL1 CAR-T Cells
Description: CD123/CLL1 CAR-T Cell Therapy
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only.
Study NCT00188578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy Boost
Description: All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
Study NCT01950819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
Study NCT01950819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Induction therapy
Description: All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
Study NCT01950819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
Study NCT01950819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
Study NCT01950819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVR+rCNI
Description: Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
Study NCT01950819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MPA+sCNI
Description: Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
Study NCT01746433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting up
Description: The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient.
Study NCT01746433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sitting up
Description: The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient.
Study NCT00531193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BIIB014
Description: oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
Study NCT00531193 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [11C]SCH442416
Description: 11C\]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. \[11C\]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
Study NCT01111604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg IV Q2W
Study NCT01111604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Icrucumab
Description: 15 mg/kg IV Q2W
Study NCT01111604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX-6
Description: Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W
Study NCT01111604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W
Study NCT02606552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatrain plus aspirin
Description: Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
Study NCT02606552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatrain plus clopidogrel
Description: Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
Study NCT02606552 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Amplazter Cardiac Plug (ACP)
Description: Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
Study NCT03607721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Motion Evaluation DARI
Description: Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
Study NCT03607721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Motion Evaluation DARI
Description: Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
Study NCT02078349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Description: Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA >2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
Study NCT04115332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bio-feedback training
Description: The aim of this study was to explore the abused PW nurses who receiving bio-feedback training as an intervention improve, and change of physiological indicators before and after intervention (3 months later), which included Respiratory Rate (RR), skin conduction (SC), heart rate variability (HRV), and resilience.
Study NCT02324725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
Study NCT02667405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot Pack
Description: Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
Study NCT02667405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whirlpool
Description: Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
Study NCT02523469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01861379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ghost Ileostomy
Description: At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
Study NCT01861379 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ghost Ileostomy
Description: At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
Study NCT03860415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx
Description: Two months of 2 sachets vivomixx each morning and 2 sachets each night. Each sachet of viviomixx contains 450 billion live bacteria.
Study NCT03860415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two months of 2 sachets placebo each morning and 2 sachets each night. Each sachet of placebo contains 450 billion live bacteria.
Study NCT00828438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10mg
Study NCT01211431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Intrathécale morphine is used for post-cesarean pain control
Study NCT01211431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
Study NCT00373438 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Fetoscopic tracheal balloon occlusion
Description: Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
Study NCT00373438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic tracheal balloon occlusion
Description: Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
Study NCT00391183 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stenting
Description: ERCP and stenting
Study NCT04306991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auscultation using an electronic stethoscope (EKO CORE 4)
Description: * Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~* Measurement of cardiac output using echocardiography.
Study NCT03616223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-322
Description: Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
Study NCT03616223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intratympanic injection
Study NCT02217774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGUIDE MORE
Description: MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
Study NCT00942071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: 1. Intradermal injection at 5 x 10\^7 pfu at day 0
Study NCT00942071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: 2.Intramuscular injection at 5 x 10\^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10\^8 pfu/ml at day 0
Study NCT00942071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: 3.Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
Study NCT05060809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vitamin k1 (phylloquinone)
Description: The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
Study NCT01917877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
Study NCT01917877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
Study NCT04986878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-shot adductor canal block
Description: An ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe was used to perform the adductor canal block immediately postoperatively.
Study NCT03962686 — intervention group
Intervention type: DRUG
Intervention: statin Oral Tablet plus PCSK9i
Description: Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
Study NCT01013467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CoCo colour coded blood pressure control
Description: The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
Study NCT03020615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Given orally once daily.
Study NCT03020615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Given orally once daily.
Study NCT01684241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBL001/RBL002
Description: Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
Study NCT01086241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Mammogram
Description: Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
Study NCT01086241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tomosynthesis
Description: Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
Study NCT05267691 — intervention group
Intervention type: PROCEDURE
Intervention: Excision
Description: Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
Study NCT02467205 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pedometer supported walking and education
Description: A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.~The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support).
Study NCT02557087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine
Study NCT03049384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise
Description: The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
Study NCT03049384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Exercise
Description: The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
Study NCT02296177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peace of Mind Program
Description: The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
Study NCT02865005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone 5.0% Gel (SEEGPharm)
Description: Topical Gel
Study NCT02865005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical Gel
Study NCT02557087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine